APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceutical (Oral Route)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Radiopharmaceutical (Oral Route) Market Analysis and Forecast 2026-2032

31 December 2025194 pages

Choose your research edition.

Industry ResearchRadiopharmaceutical (Oral Route) Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceutical (Oral Route) Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Radiopharmaceutical (Oral Route) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceutical (Oral Route) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceutical (Oral Route) Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Radiopharmaceutical (Oral Route) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Radiopharmaceutical (Oral Route) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Radiopharmaceutical (Oral Route) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Radiopharmaceutical (Oral Route) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Radiopharmaceutical (Oral Route) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Radiopharmaceutical (Oral Route) include Eli Lilly, Bayer, Triad Isotopes, SIEMENS, Nordion, Navidea, Mallinckrodt, Lantheus and Jubilant Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Radiopharmaceutical (Oral Route), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Radiopharmaceutical (Oral Route), also provides the sales of main regions and countries. Of the upcoming market potential for Radiopharmaceutical (Oral Route), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Radiopharmaceutical (Oral Route) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Radiopharmaceutical (Oral Route) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Radiopharmaceutical (Oral Route) sales, projected growth trends, production technology, application and end-user industry.

Radiopharmaceutical (Oral Route) Segment by Company

Eli Lilly

Bayer

Triad Isotopes

SIEMENS

Nordion

Navidea

Mallinckrodt

Lantheus

Jubilant Pharma

IBA Group

GE Healthcare

Dongcheng

China Isotope & Radiation

Bracco Imaging

Advanced Accelerator Applications

Radiopharmaceutical (Oral Route) Segment by Type

Actinium-225

Holmium-166

Radium-223

Lutetium-177

Other

Radiopharmaceutical (Oral Route) Segment by Application

Oncology

Cardiology

Other

Radiopharmaceutical (Oral Route) Segment by Region

North America

United States

Canada

Europe

v

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical (Oral Route) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical (Oral Route) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical (Oral Route).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Radiopharmaceutical (Oral Route) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Radiopharmaceutical (Oral Route) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radiopharmaceutical (Oral Route) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Radiopharmaceutical (Oral Route) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Actinium-225 Major Manufacturers Table 3. Holmium-166 Major Manufacturers Table 4. Radium-223 Major Manufacturers Table 5. Lutetium-177 Major Manufacturers Table 6. Other Major Manufacturers Table 7. Global Radiopharmaceutical (Oral Route) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Oncology Major Manufacturers Table 9. Cardiology Major Manufacturers Table 10. Other Major Manufacturers Table 11. Radiopharmaceutical (Oral Route) Industry Trends Table 12. Radiopharmaceutical (Oral Route) Industry Drivers Table 13. Radiopharmaceutical (Oral Route) Industry Opportunities and Challenges Table 14. Radiopharmaceutical (Oral Route) Industry Restraints Table 15. Global Radiopharmaceutical (Oral Route) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Radiopharmaceutical (Oral Route) Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Radiopharmaceutical (Oral Route) Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2021-2026) Table 19. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2027-2032) Table 20. Global Radiopharmaceutical (Oral Route) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Radiopharmaceutical (Oral Route) Sales by Region (2021-2026) & (K Units) Table 22. Global Radiopharmaceutical (Oral Route) Sales by Region (2027-2032) & (K Units) Table 23. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2021-2026) Table 24. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2027-2032) Table 25. Global Radiopharmaceutical (Oral Route) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Radiopharmaceutical (Oral Route) Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Radiopharmaceutical (Oral Route) Sales Market Share by Manufacturers (2021-2026) Table 29. Global Radiopharmaceutical (Oral Route) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Radiopharmaceutical (Oral Route) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Radiopharmaceutical (Oral Route) Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Radiopharmaceutical (Oral Route) Manufacturers, Product Type & Application Table 33. Global Radiopharmaceutical (Oral Route) Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Radiopharmaceutical (Oral Route) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Radiopharmaceutical (Oral Route) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Radiopharmaceutical (Oral Route) Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Radiopharmaceutical (Oral Route) Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2021-2026) Table 40. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2027-2032) Table 41. Global Radiopharmaceutical (Oral Route) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Radiopharmaceutical (Oral Route) Sales by Type (2021-2026) & (K Units) Table 43. Global Radiopharmaceutical (Oral Route) Sales by Type (2027-2032) & (K Units) Table 44. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2021-2026) Table 45. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2027-2032) Table 46. Global Radiopharmaceutical (Oral Route) Price by Type (2021-2026) & (US$/Unit) Table 47. Global Radiopharmaceutical (Oral Route) Price by Type (2027-2032) & (US$/Unit) Table 48. Global Radiopharmaceutical (Oral Route) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Radiopharmaceutical (Oral Route) Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Radiopharmaceutical (Oral Route) Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2021-2026) Table 52. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2027-2032) Table 53. Global Radiopharmaceutical (Oral Route) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Radiopharmaceutical (Oral Route) Sales by Application (2021-2026) & (K Units) Table 55. Global Radiopharmaceutical (Oral Route) Sales by Application (2027-2032) & (K Units) Table 56. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2021-2026) Table 57. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2027-2032) Table 58. Global Radiopharmaceutical (Oral Route) Price by Application (2021-2026) & (US$/Unit) Table 59. Global Radiopharmaceutical (Oral Route) Price by Application (2027-2032) & (US$/Unit) Table 60. Eli Lilly Company Information Table 61. Eli Lilly Business Overview Table 62. Eli Lilly Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Eli Lilly Radiopharmaceutical (Oral Route) Product Portfolio Table 64. Eli Lilly Recent Development Table 65. Bayer Company Information Table 66. Bayer Business Overview Table 67. Bayer Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Bayer Radiopharmaceutical (Oral Route) Product Portfolio Table 69. Bayer Recent Development Table 70. Triad Isotopes Company Information Table 71. Triad Isotopes Business Overview Table 72. Triad Isotopes Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Triad Isotopes Radiopharmaceutical (Oral Route) Product Portfolio Table 74. Triad Isotopes Recent Development Table 75. SIEMENS Company Information Table 76. SIEMENS Business Overview Table 77. SIEMENS Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. SIEMENS Radiopharmaceutical (Oral Route) Product Portfolio Table 79. SIEMENS Recent Development Table 80. Nordion Company Information Table 81. Nordion Business Overview Table 82. Nordion Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Nordion Radiopharmaceutical (Oral Route) Product Portfolio Table 84. Nordion Recent Development Table 85. Navidea Company Information Table 86. Navidea Business Overview Table 87. Navidea Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Navidea Radiopharmaceutical (Oral Route) Product Portfolio Table 89. Navidea Recent Development Table 90. Mallinckrodt Company Information Table 91. Mallinckrodt Business Overview Table 92. Mallinckrodt Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Mallinckrodt Radiopharmaceutical (Oral Route) Product Portfolio Table 94. Mallinckrodt Recent Development Table 95. Lantheus Company Information Table 96. Lantheus Business Overview Table 97. Lantheus Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Lantheus Radiopharmaceutical (Oral Route) Product Portfolio Table 99. Lantheus Recent Development Table 100. Jubilant Pharma Company Information Table 101. Jubilant Pharma Business Overview Table 102. Jubilant Pharma Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Jubilant Pharma Radiopharmaceutical (Oral Route) Product Portfolio Table 104. Jubilant Pharma Recent Development Table 105. IBA Group Company Information Table 106. IBA Group Business Overview Table 107. IBA Group Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. IBA Group Radiopharmaceutical (Oral Route) Product Portfolio Table 109. IBA Group Recent Development Table 110. GE Healthcare Company Information Table 111. GE Healthcare Business Overview Table 112. GE Healthcare Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. GE Healthcare Radiopharmaceutical (Oral Route) Product Portfolio Table 114. GE Healthcare Recent Development Table 115. Dongcheng Company Information Table 116. Dongcheng Business Overview Table 117. Dongcheng Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Dongcheng Radiopharmaceutical (Oral Route) Product Portfolio Table 119. Dongcheng Recent Development Table 120. China Isotope & Radiation Company Information Table 121. China Isotope & Radiation Business Overview Table 122. China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Portfolio Table 124. China Isotope & Radiation Recent Development Table 125. Bracco Imaging Company Information Table 126. Bracco Imaging Business Overview Table 127. Bracco Imaging Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Bracco Imaging Radiopharmaceutical (Oral Route) Product Portfolio Table 129. Bracco Imaging Recent Development Table 130. Advanced Accelerator Applications Company Information Table 131. Advanced Accelerator Applications Business Overview Table 132. Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Portfolio Table 134. Advanced Accelerator Applications Recent Development Table 135. North America Radiopharmaceutical (Oral Route) Revenue by Type (2021-2026) & (US$ Million) Table 136. North America Radiopharmaceutical (Oral Route) Revenue by Type (2027-2032) & (US$ Million) Table 137. North America Radiopharmaceutical (Oral Route) Sales by Type (2021-2026) & (K Units) Table 138. North America Radiopharmaceutical (Oral Route) Sales by Type (2027-2032) & (K Units) Table 139. North America Radiopharmaceutical (Oral Route) Sales Price by Type (2021-2026) & (US$/Unit) Table 140. North America Radiopharmaceutical (Oral Route) Sales Price by Type (2027-2032) & (US$/Unit) Table 141. North America Radiopharmaceutical (Oral Route) Revenue by Application (2021-2026) & (US$ Million) Table 142. North America Radiopharmaceutical (Oral Route) Revenue by Application (2027-2032) & (US$ Million) Table 143. North America Radiopharmaceutical (Oral Route) Sales by Application (2021-2026) & (K Units) Table 144. North America Radiopharmaceutical (Oral Route) Sales by Application (2027-2032) & (K Units) Table 145. North America Radiopharmaceutical (Oral Route) Sales Price by Application (2021-2026) & (US$/Unit) Table 146. North America Radiopharmaceutical (Oral Route) Sales Price by Application (2027-2032) & (US$/Unit) Table 147. North America Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 148. North America Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 149. North America Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 150. North America Radiopharmaceutical (Oral Route) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 151. North America Radiopharmaceutical (Oral Route) Sales by Country (2021-2026) & (K Units) Table 152. North America Radiopharmaceutical (Oral Route) Sales by Country (2027-2032) & (K Units) Table 153. North America Radiopharmaceutical (Oral Route) Sales Price by Country (2021-2026) & (US$/Unit) Table 154. North America Radiopharmaceutical (Oral Route) Sales Price by Country (2027-2032) & (US$/Unit) Table 155. United States Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 156. Canada Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 157. Europe Radiopharmaceutical (Oral Route) Revenue by Type (2021-2026) & (US$ Million) Table 158. Europe Radiopharmaceutical (Oral Route) Revenue by Type (2027-2032) & (US$ Million) Table 159. Europe Radiopharmaceutical (Oral Route) Sales by Type (2021-2026) & (K Units) Table 160. Europe Radiopharmaceutical (Oral Route) Sales by Type (2027-2032) & (K Units) Table 161. Europe Radiopharmaceutical (Oral Route) Sales Price by Type (2021-2026) & (US$/Unit) Table 162. Europe Radiopharmaceutical (Oral Route) Sales Price by Type (2027-2032) & (US$/Unit) Table 163. Europe Radiopharmaceutical (Oral Route) Revenue by Application (2021-2026) & (US$ Million) Table 164. Europe Radiopharmaceutical (Oral Route) Revenue by Application (2027-2032) & (US$ Million) Table 165. Europe Radiopharmaceutical (Oral Route) Sales by Application (2021-2026) & (K Units) Table 166. Europe Radiopharmaceutical (Oral Route) Sales by Application (2027-2032) & (K Units) Table 167. Europe Radiopharmaceutical (Oral Route) Sales Price by Application (2021-2026) & (US$/Unit) Table 168. Europe Radiopharmaceutical (Oral Route) Sales Price by Application (2027-2032) & (US$/Unit) Table 169. Europe Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. Europe Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 171. Europe Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 172. Europe Radiopharmaceutical (Oral Route) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 173. Europe Radiopharmaceutical (Oral Route) Sales by Country (2021-2026) & (K Units) Table 174. Europe Radiopharmaceutical (Oral Route) Sales by Country (2027-2032) & (K Units) Table 175. Europe Radiopharmaceutical (Oral Route) Sales Price by Country (2021-2026) & (US$/Unit) Table 176. Europe Radiopharmaceutical (Oral Route) Sales Price by Country (2027-2032) & (US$/Unit) Table 177. v Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 178. France Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 179. U.K. Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 180. Italy Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 181. Netherlands Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 182. China Radiopharmaceutical (Oral Route) Revenue by Type (2021-2026) & (US$ Million) Table 183. China Radiopharmaceutical (Oral Route) Revenue by Type (2027-2032) & (US$ Million) Table 184. China Radiopharmaceutical (Oral Route) Sales by Type (2021-2026) & (K Units) Table 185. China Radiopharmaceutical (Oral Route) Sales by Type (2027-2032) & (K Units) Table 186. China Radiopharmaceutical (Oral Route) Sales Price by Type (2021-2026) & (US$/Unit) Table 187. China Radiopharmaceutical (Oral Route) Sales Price by Type (2027-2032) & (US$/Unit) Table 188. China Radiopharmaceutical (Oral Route) Revenue by Application (2021-2026) & (US$ Million) Table 189. China Radiopharmaceutical (Oral Route) Revenue by Application (2027-2032) & (US$ Million) Table 190. China Radiopharmaceutical (Oral Route) Sales by Application (2021-2026) & (K Units) Table 191. China Radiopharmaceutical (Oral Route) Sales by Application (2027-2032) & (K Units) Table 192. China Radiopharmaceutical (Oral Route) Sales Price by Application (2021-2026) & (US$/Unit) Table 193. China Radiopharmaceutical (Oral Route) Sales Price by Application (2027-2032) & (US$/Unit) Table 194. Asia Radiopharmaceutical (Oral Route) Revenue by Type (2021-2026) & (US$ Million) Table 195. Asia Radiopharmaceutical (Oral Route) Revenue by Type (2027-2032) & (US$ Million) Table 196. Asia Radiopharmaceutical (Oral Route) Sales by Type (2021-2026) & (K Units) Table 197. Asia Radiopharmaceutical (Oral Route) Sales by Type (2027-2032) & (K Units) Table 198. Asia Radiopharmaceutical (Oral Route) Sales Price by Type (2021-2026) & (US$/Unit) Table 199. Asia Radiopharmaceutical (Oral Route) Sales Price by Type (2027-2032) & (US$/Unit) Table 200. Asia Radiopharmaceutical (Oral Route) Revenue by Application (2021-2026) & (US$ Million) Table 201. Asia Radiopharmaceutical (Oral Route) Revenue by Application (2027-2032) & (US$ Million) Table 202. Asia Radiopharmaceutical (Oral Route) Sales by Application (2021-2026) & (K Units) Table 203. Asia Radiopharmaceutical (Oral Route) Sales by Application (2027-2032) & (K Units) Table 204. Asia Radiopharmaceutical (Oral Route) Sales Price by Application (2021-2026) & (US$/Unit) Table 205. Asia Radiopharmaceutical (Oral Route) Sales Price by Application (2027-2032) & (US$/Unit) Table 206. Asia Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 207. Asia Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 208. Asia Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 209. Asia Radiopharmaceutical (Oral Route) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 210. Asia Radiopharmaceutical (Oral Route) Sales by Country (2021-2026) & (K Units) Table 211. Asia Radiopharmaceutical (Oral Route) Sales by Country (2027-2032) & (K Units) Table 212. Asia Radiopharmaceutical (Oral Route) Sales Price by Country (2021-2026) & (US$/Unit) Table 213. Asia Radiopharmaceutical (Oral Route) Sales Price by Country (2027-2032) & (US$/Unit) Table 214. Japan Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 215. South Korea Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 216. India Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 217. Australia Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 218. China Taiwan Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 219. Southeast Asia Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 220. SAMEA Radiopharmaceutical (Oral Route) Revenue by Type (2021-2026) & (US$ Million) Table 221. SAMEA Radiopharmaceutical (Oral Route) Revenue by Type (2027-2032) & (US$ Million) Table 222. SAMEA Radiopharmaceutical (Oral Route) Sales by Type (2021-2026) & (K Units) Table 223. SAMEA Radiopharmaceutical (Oral Route) Sales by Type (2027-2032) & (K Units) Table 224. SAMEA Radiopharmaceutical (Oral Route) Sales Price by Type (2021-2026) & (US$/Unit) Table 225. SAMEA Radiopharmaceutical (Oral Route) Sales Price by Type (2027-2032) & (US$/Unit) Table 226. SAMEA Radiopharmaceutical (Oral Route) Revenue by Application (2021-2026) & (US$ Million) Table 227. SAMEA Radiopharmaceutical (Oral Route) Revenue by Application (2027-2032) & (US$ Million) Table 228. SAMEA Radiopharmaceutical (Oral Route) Sales by Application (2021-2026) & (K Units) Table 229. SAMEA Radiopharmaceutical (Oral Route) Sales by Application (2027-2032) & (K Units) Table 230. SAMEA Radiopharmaceutical (Oral Route) Sales Price by Application (2021-2026) & (US$/Unit) Table 231. SAMEA Radiopharmaceutical (Oral Route) Sales Price by Application (2027-2032) & (US$/Unit) Table 232. SAMEA Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 233. SAMEA Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 234. SAMEA Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 235. SAMEA Radiopharmaceutical (Oral Route) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 236. SAMEA Radiopharmaceutical (Oral Route) Sales by Country (2021-2026) & (K Units) Table 237. SAMEA Radiopharmaceutical (Oral Route) Sales by Country (2027-2032) & (K Units) Table 238. SAMEA Radiopharmaceutical (Oral Route) Sales Price by Country (2021-2026) & (US$/Unit) Table 239. SAMEA Radiopharmaceutical (Oral Route) Sales Price by Country (2027-2032) & (US$/Unit) Table 240. Brazil Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 241. Argentina Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 242. Chile Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 243. Colombia Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 244. Peru Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 245. Saudi Arabia Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 246. Israel Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 247. UAE Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 248. Turkey Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 249. Iran Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 250. Egypt Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Table 251. Key Raw Materials Table 252. Raw Materials Key Suppliers Table 253. Radiopharmaceutical (Oral Route) Distributors List Table 254. Radiopharmaceutical (Oral Route) Customers List Table 255. Research Programs/Design for This Report Table 256. Authors List of This Report Table 257. Secondary Sources Table 258. Primary Sources List of Figures Figure 1. Radiopharmaceutical (Oral Route) Image Figure 2. Global Radiopharmaceutical (Oral Route) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiopharmaceutical (Oral Route) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Actinium-225 Image Figure 5. Holmium-166 Image Figure 6. Radium-223 Image Figure 7. Lutetium-177 Image Figure 8. Other Image Figure 9. Global Radiopharmaceutical (Oral Route) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Radiopharmaceutical (Oral Route) Market Size Share 2021 VS 2025 VS 2032 Figure 11. Oncology Image Figure 12. Cardiology Image Figure 13. Other Image Figure 14. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Figure 16. Global Radiopharmaceutical (Oral Route) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2021-2032) Figure 19. Global Radiopharmaceutical (Oral Route) Sales (2021-2032) & (K Units) Figure 20. Global Radiopharmaceutical (Oral Route) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Radiopharmaceutical (Oral Route) Sales YoY (2021-2032) & (K Units) Figure 23. Europe Radiopharmaceutical (Oral Route) Sales YoY (2021-2032) & (K Units) Figure 24. China Radiopharmaceutical (Oral Route) Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Radiopharmaceutical (Oral Route) Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Radiopharmaceutical (Oral Route) Sales YoY (2021-2032) & (K Units) Figure 27. Global Radiopharmaceutical (Oral Route) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Radiopharmaceutical (Oral Route) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Radiopharmaceutical (Oral Route) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2021-2032) Figure 33. Global Radiopharmaceutical (Oral Route) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2021-2032) Figure 36. Global Radiopharmaceutical (Oral Route) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2021-2032) Figure 39. Global Radiopharmaceutical (Oral Route) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2021-2032) Figure 42. North America Radiopharmaceutical (Oral Route) Revenue Share by Type (2021-2032) Figure 43. North America Radiopharmaceutical (Oral Route) Sales Share by Type (2021-2032) Figure 44. North America Radiopharmaceutical (Oral Route) Revenue Share by Application (2021-2032) Figure 45. North America Radiopharmaceutical (Oral Route) Sales Share by Application (2021-2032) Figure 46. North America Radiopharmaceutical (Oral Route) Revenue Share by Country (2021-2032) Figure 47. North America Radiopharmaceutical (Oral Route) Sales Share by Country (2021-2032) Figure 48. Europe Radiopharmaceutical (Oral Route) Revenue Share by Type (2021-2032) Figure 49. Europe Radiopharmaceutical (Oral Route) Sales Share by Type (2021-2032) Figure 50. Europe Radiopharmaceutical (Oral Route) Revenue Share by Application (2021-2032) Figure 51. Europe Radiopharmaceutical (Oral Route) Sales Share by Application (2021-2032) Figure 52. Europe Radiopharmaceutical (Oral Route) Revenue Share by Country (2021-2032) Figure 53. Europe Radiopharmaceutical (Oral Route) Sales Share by Country (2021-2032) Figure 54. China Radiopharmaceutical (Oral Route) Revenue Share by Type (2021-2032) Figure 55. China Radiopharmaceutical (Oral Route) Sales Share by Type (2021-2032) Figure 56. China Radiopharmaceutical (Oral Route) Revenue Share by Application (2021-2032) Figure 57. China Radiopharmaceutical (Oral Route) Sales Share by Application (2021-2032) Figure 58. Asia Radiopharmaceutical (Oral Route) Revenue Share by Type (2021-2032) Figure 59. Asia Radiopharmaceutical (Oral Route) Sales Share by Type (2021-2032) Figure 60. Asia Radiopharmaceutical (Oral Route) Revenue Share by Application (2021-2032) Figure 61. Asia Radiopharmaceutical (Oral Route) Sales Share by Application (2021-2032) Figure 62. Asia Radiopharmaceutical (Oral Route) Revenue Share by Country (2021-2032) Figure 63. Asia Radiopharmaceutical (Oral Route) Sales Share by Country (2021-2032) Figure 64. SAMEA Radiopharmaceutical (Oral Route) Revenue Share by Type (2021-2032) Figure 65. SAMEA Radiopharmaceutical (Oral Route) Sales Share by Type (2021-2032) Figure 66. SAMEA Radiopharmaceutical (Oral Route) Revenue Share by Application (2021-2032) Figure 67. SAMEA Radiopharmaceutical (Oral Route) Sales Share by Application (2021-2032) Figure 68. SAMEA Radiopharmaceutical (Oral Route) Revenue Share by Country (2021-2032) Figure 69. SAMEA Radiopharmaceutical (Oral Route) Sales Share by Country (2021-2032) Figure 70. Radiopharmaceutical (Oral Route) Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Radiopharmaceutical (Oral Route) Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Actinium-225
  • Holmium-166
  • Radium-223
  • Lutetium-177
  • Other
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Eli Lilly
  • Bayer
  • Triad Isotopes
  • SIEMENS
  • Nordion
  • Navidea
  • Mallinckrodt
  • Lantheus
  • Jubilant Pharma
  • IBA Group
  • GE Healthcare
  • Dongcheng
  • China Isotope & Radiation
  • Bracco Imaging
  • Advanced Accelerator Applications

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Radiopharmaceutical (Oral Route) Market by Type
  3. 1.2.1 Global Radiopharmaceutical (Oral Route) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Actinium-225
  5. 1.2.3 Holmium-166
  6. 1.2.4 Radium-223
  7. 1.2.5 Lutetium-177
  8. 1.2.6 Other
  9. 1.3 Radiopharmaceutical (Oral Route) Market by Application
  10. 1.3.1 Global Radiopharmaceutical (Oral Route) Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Oncology
  12. 1.3.3 Cardiology
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Radiopharmaceutical (Oral Route) Market Dynamics
  1. 2.1 Radiopharmaceutical (Oral Route) Industry Trends
  2. 2.2 Radiopharmaceutical (Oral Route) Industry Drivers
  3. 2.3 Radiopharmaceutical (Oral Route) Industry Opportunities and Challenges
  4. 2.4 Radiopharmaceutical (Oral Route) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Radiopharmaceutical (Oral Route) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Radiopharmaceutical (Oral Route) Revenue by Region
  3. 3.2.1 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Radiopharmaceutical (Oral Route) Revenue by Region (2021-2026)
  5. 3.2.3 Global Radiopharmaceutical (Oral Route) Revenue by Region (2027-2032)
  6. 3.2.4 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Radiopharmaceutical (Oral Route) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Radiopharmaceutical (Oral Route) Sales by Region
  9. 3.4.1 Global Radiopharmaceutical (Oral Route) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Radiopharmaceutical (Oral Route) Sales by Region (2021-2026)
  11. 3.4.3 Global Radiopharmaceutical (Oral Route) Sales by Region (2027-2032)
  12. 3.4.4 Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Radiopharmaceutical (Oral Route) Revenue by Manufacturers
  2. 4.1.1 Global Radiopharmaceutical (Oral Route) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Radiopharmaceutical (Oral Route) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Radiopharmaceutical (Oral Route) Sales by Manufacturers
  6. 4.2.1 Global Radiopharmaceutical (Oral Route) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Radiopharmaceutical (Oral Route) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Radiopharmaceutical (Oral Route) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Radiopharmaceutical (Oral Route) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Radiopharmaceutical (Oral Route) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Radiopharmaceutical (Oral Route) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Radiopharmaceutical (Oral Route) Manufacturers, Product Type & Application
  13. 4.7 Global Radiopharmaceutical (Oral Route) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Radiopharmaceutical (Oral Route) Market CR5 and HHI
  16. 4.8.2 2025 Radiopharmaceutical (Oral Route) Tier 1, Tier 2, and Tier 3
5 Radiopharmaceutical (Oral Route) Market by Type
  1. 5.1 Global Radiopharmaceutical (Oral Route) Revenue by Type
  2. 5.1.1 Global Radiopharmaceutical (Oral Route) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Radiopharmaceutical (Oral Route) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Radiopharmaceutical (Oral Route) Sales by Type
  6. 5.2.1 Global Radiopharmaceutical (Oral Route) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Radiopharmaceutical (Oral Route) Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Radiopharmaceutical (Oral Route) Price by Type
6 Radiopharmaceutical (Oral Route) Market by Application
  1. 6.1 Global Radiopharmaceutical (Oral Route) Revenue by Application
  2. 6.1.1 Global Radiopharmaceutical (Oral Route) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Radiopharmaceutical (Oral Route) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Radiopharmaceutical (Oral Route) Sales by Application
  6. 6.2.1 Global Radiopharmaceutical (Oral Route) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Radiopharmaceutical (Oral Route) Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Radiopharmaceutical (Oral Route) Price by Application
7 Company Profiles
  1. 7.1 Eli Lilly
  2. 7.1.1 Eli Lilly Company Information
  3. 7.1.2 Eli Lilly Business Overview
  4. 7.1.3 Eli Lilly Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Eli Lilly Radiopharmaceutical (Oral Route) Product Portfolio
  6. 7.1.5 Eli Lilly Recent Developments
  7. 7.2 Bayer
  8. 7.2.1 Bayer Company Information
  9. 7.2.2 Bayer Business Overview
  10. 7.2.3 Bayer Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bayer Radiopharmaceutical (Oral Route) Product Portfolio
  12. 7.2.5 Bayer Recent Developments
  13. 7.3 Triad Isotopes
  14. 7.3.1 Triad Isotopes Company Information
  15. 7.3.2 Triad Isotopes Business Overview
  16. 7.3.3 Triad Isotopes Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Triad Isotopes Radiopharmaceutical (Oral Route) Product Portfolio
  18. 7.3.5 Triad Isotopes Recent Developments
  19. 7.4 SIEMENS
  20. 7.4.1 SIEMENS Company Information
  21. 7.4.2 SIEMENS Business Overview
  22. 7.4.3 SIEMENS Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 SIEMENS Radiopharmaceutical (Oral Route) Product Portfolio
  24. 7.4.5 SIEMENS Recent Developments
  25. 7.5 Nordion
  26. 7.5.1 Nordion Company Information
  27. 7.5.2 Nordion Business Overview
  28. 7.5.3 Nordion Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Nordion Radiopharmaceutical (Oral Route) Product Portfolio
  30. 7.5.5 Nordion Recent Developments
  31. 7.6 Navidea
  32. 7.6.1 Navidea Company Information
  33. 7.6.2 Navidea Business Overview
  34. 7.6.3 Navidea Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Navidea Radiopharmaceutical (Oral Route) Product Portfolio
  36. 7.6.5 Navidea Recent Developments
  37. 7.7 Mallinckrodt
  38. 7.7.1 Mallinckrodt Company Information
  39. 7.7.2 Mallinckrodt Business Overview
  40. 7.7.3 Mallinckrodt Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Mallinckrodt Radiopharmaceutical (Oral Route) Product Portfolio
  42. 7.7.5 Mallinckrodt Recent Developments
  43. 7.8 Lantheus
  44. 7.8.1 Lantheus Company Information
  45. 7.8.2 Lantheus Business Overview
  46. 7.8.3 Lantheus Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Lantheus Radiopharmaceutical (Oral Route) Product Portfolio
  48. 7.8.5 Lantheus Recent Developments
  49. 7.9 Jubilant Pharma
  50. 7.9.1 Jubilant Pharma Company Information
  51. 7.9.2 Jubilant Pharma Business Overview
  52. 7.9.3 Jubilant Pharma Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Jubilant Pharma Radiopharmaceutical (Oral Route) Product Portfolio
  54. 7.9.5 Jubilant Pharma Recent Developments
  55. 7.10 IBA Group
  56. 7.10.1 IBA Group Company Information
  57. 7.10.2 IBA Group Business Overview
  58. 7.10.3 IBA Group Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 IBA Group Radiopharmaceutical (Oral Route) Product Portfolio
  60. 7.10.5 IBA Group Recent Developments
  61. 7.11 GE Healthcare
  62. 7.11.1 GE Healthcare Company Information
  63. 7.11.2 GE Healthcare Business Overview
  64. 7.11.3 GE Healthcare Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 GE Healthcare Radiopharmaceutical (Oral Route) Product Portfolio
  66. 7.11.5 GE Healthcare Recent Developments
  67. 7.12 Dongcheng
  68. 7.12.1 Dongcheng Company Information
  69. 7.12.2 Dongcheng Business Overview
  70. 7.12.3 Dongcheng Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Dongcheng Radiopharmaceutical (Oral Route) Product Portfolio
  72. 7.12.5 Dongcheng Recent Developments
  73. 7.13 China Isotope & Radiation
  74. 7.13.1 China Isotope & Radiation Company Information
  75. 7.13.2 China Isotope & Radiation Business Overview
  76. 7.13.3 China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Portfolio
  78. 7.13.5 China Isotope & Radiation Recent Developments
  79. 7.14 Bracco Imaging
  80. 7.14.1 Bracco Imaging Company Information
  81. 7.14.2 Bracco Imaging Business Overview
  82. 7.14.3 Bracco Imaging Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Bracco Imaging Radiopharmaceutical (Oral Route) Product Portfolio
  84. 7.14.5 Bracco Imaging Recent Developments
  85. 7.15 Advanced Accelerator Applications
  86. 7.15.1 Advanced Accelerator Applications Company Information
  87. 7.15.2 Advanced Accelerator Applications Business Overview
  88. 7.15.3 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Portfolio
  90. 7.15.5 Advanced Accelerator Applications Recent Developments
8 North America
  1. 8.1 North America Radiopharmaceutical (Oral Route) Market Size by Type
  2. 8.1.1 North America Radiopharmaceutical (Oral Route) Revenue by Type (2021-2032)
  3. 8.1.2 North America Radiopharmaceutical (Oral Route) Sales by Type (2021-2032)
  4. 8.1.3 North America Radiopharmaceutical (Oral Route) Price by Type (2021-2032)
  5. 8.2 North America Radiopharmaceutical (Oral Route) Market Size by Application
  6. 8.2.1 North America Radiopharmaceutical (Oral Route) Revenue by Application (2021-2032)
  7. 8.2.2 North America Radiopharmaceutical (Oral Route) Sales by Application (2021-2032)
  8. 8.2.3 North America Radiopharmaceutical (Oral Route) Price by Application (2021-2032)
  9. 8.3 North America Radiopharmaceutical (Oral Route) Market Size by Country
  10. 8.3.1 North America Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Radiopharmaceutical (Oral Route) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Radiopharmaceutical (Oral Route) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Radiopharmaceutical (Oral Route) Market Size by Type
  2. 9.1.1 Europe Radiopharmaceutical (Oral Route) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Radiopharmaceutical (Oral Route) Sales by Type (2021-2032)
  4. 9.1.3 Europe Radiopharmaceutical (Oral Route) Price by Type (2021-2032)
  5. 9.2 Europe Radiopharmaceutical (Oral Route) Market Size by Application
  6. 9.2.1 Europe Radiopharmaceutical (Oral Route) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Radiopharmaceutical (Oral Route) Sales by Application (2021-2032)
  8. 9.2.3 Europe Radiopharmaceutical (Oral Route) Price by Application (2021-2032)
  9. 9.3 Europe Radiopharmaceutical (Oral Route) Market Size by Country
  10. 9.3.1 Europe Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Radiopharmaceutical (Oral Route) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Radiopharmaceutical (Oral Route) Price by Country (2021-2032)
  13. 9.3.4 v
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Radiopharmaceutical (Oral Route) Market Size by Type
  2. 10.1.1 China Radiopharmaceutical (Oral Route) Revenue by Type (2021-2032)
  3. 10.1.2 China Radiopharmaceutical (Oral Route) Sales by Type (2021-2032)
  4. 10.1.3 China Radiopharmaceutical (Oral Route) Price by Type (2021-2032)
  5. 10.2 China Radiopharmaceutical (Oral Route) Market Size by Application
  6. 10.2.1 China Radiopharmaceutical (Oral Route) Revenue by Application (2021-2032)
  7. 10.2.2 China Radiopharmaceutical (Oral Route) Sales by Application (2021-2032)
  8. 10.2.3 China Radiopharmaceutical (Oral Route) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Radiopharmaceutical (Oral Route) Market Size by Type
  2. 11.1.1 Asia Radiopharmaceutical (Oral Route) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Radiopharmaceutical (Oral Route) Sales by Type (2021-2032)
  4. 11.1.3 Asia Radiopharmaceutical (Oral Route) Price by Type (2021-2032)
  5. 11.2 Asia Radiopharmaceutical (Oral Route) Market Size by Application
  6. 11.2.1 Asia Radiopharmaceutical (Oral Route) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Radiopharmaceutical (Oral Route) Sales by Application (2021-2032)
  8. 11.2.3 Asia Radiopharmaceutical (Oral Route) Price by Application (2021-2032)
  9. 11.3 Asia Radiopharmaceutical (Oral Route) Market Size by Country
  10. 11.3.1 Asia Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Radiopharmaceutical (Oral Route) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Radiopharmaceutical (Oral Route) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Radiopharmaceutical (Oral Route) Market Size by Type
  2. 12.1.1 SAMEA Radiopharmaceutical (Oral Route) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Radiopharmaceutical (Oral Route) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Radiopharmaceutical (Oral Route) Price by Type (2021-2032)
  5. 12.2 SAMEA Radiopharmaceutical (Oral Route) Market Size by Application
  6. 12.2.1 SAMEA Radiopharmaceutical (Oral Route) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Radiopharmaceutical (Oral Route) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Radiopharmaceutical (Oral Route) Price by Application (2021-2032)
  9. 12.3 SAMEA Radiopharmaceutical (Oral Route) Market Size by Country
  10. 12.3.1 SAMEA Radiopharmaceutical (Oral Route) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Radiopharmaceutical (Oral Route) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Radiopharmaceutical (Oral Route) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Radiopharmaceutical (Oral Route) Value Chain Analysis
  2. 13.1.1 Radiopharmaceutical (Oral Route) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Radiopharmaceutical (Oral Route) Production Mode & Process
  6. 13.2 Radiopharmaceutical (Oral Route) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Radiopharmaceutical (Oral Route) Distributors
  9. 13.2.3 Radiopharmaceutical (Oral Route) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst